부산대학교 도서관

Aim: We aimed to evaluate the 1-year efficacy and safety of low-frequency intravitreal bevacizumab in the treatment of macular edema due to retinal vein occlusions (RVOs). Methods: The study comprised an interventional prospective study of patients with macular edema due to central retinal vein occlusion (CRVO) or branch retinal vein occlusion, followed for 12 months. Treatment-naive patients with reduced best-corrected visual acuity (BCVA) and central macular thickness (CMT) of at least 250 [micro]m received intravitreal injection of bevacizumab. After 1 month, BCVA and optical coherence tomography (OCT) images of the macula were recorded. In patients with Results: In total, 33 patients with CRVO and 55 with BRVO were treated. After 1 year, 65 eyes (73.86%) had clinically significant improvement of BCVA (>0.3 log of the minimum angle of resolution [logMAR] units) with average number of injections of 1.98. Improvement of mean BCVA in CRVO was significant (P=0.001) from baseline (1.2[+ or -]0.95 logMAR units) to 1 year (0.75[+ or -]0.6 logMAR units). Significant improvement of mean BCVA (P Conclusion: In macular edema due to RVO, intravitreal bevacizumab provides improvement in visual acuity and reduction of macular edema in a high percentage of treated eyes after 1 year, even with low number of injections. Keywords: macular edema, retinal vein occlusion, bevacizumab, intravitreal injection
Background Retinal vein occlusion (RVO) is the most common retinal vascular disease, after diabetic retinopathy. (1) Epidemiological studies have shown that RVO prevalence varies from 0.3% (2) to 1.6% (3) [...]